Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial | Zendy

Harold P. Adams | Zendy; Mark B. Effron | Zendy; James C. Torner | Zendy; Antoni Dávalos | Zendy; Judith Frayne | Zendy; Philip Teal | Zendy; Jacques Leclerc | Zendy; Barry S. Oemar | Zendy; Lakshmi Padgett | Zendy; Elliot S. Barnathan | Zendy; Werner Hacke | Zendy

Open Access

Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial

Author(s) -

Harold P. Adams,

Mark B. Effron,

James C. Torner,

Antoni Dávalos,

Judith Frayne,

Philip Teal,

Jacques Leclerc,

Barry S. Oemar,

Lakshmi Padgett,

Elliot S. Barnathan,

Werner Hacke

Publication year - 2007

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.106.476648

Subject(s) - medicine , abciximab , stroke (engine) , ischemic stroke , acute stroke , endovascular treatment , emergency medicine , ischemia , surgery , myocardial infarction , tissue plasminogen activator , percutaneous coronary intervention , aneurysm , mechanical engineering , engineering

A previous randomized, placebo-controlled, double-blind study suggested that abciximab may be safe and effective in treatment of acute ischemic stroke. The current phase 3 study was planned to test the relative efficacy and safety of abciximab in patients with acute ischemic stroke with planned treatment within 5 hours since symptoms onset.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research